Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.59 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.59 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.52 |
| ▸ | ABCC2 | Q92887 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.52 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530485 | 1.00 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL626121 | 1.00 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL27878813 | 0.88 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL28026167 | 0.88 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL27878868 | 0.88 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL27970791 | 0.88 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL28947806 | 0.88 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL15748690 | 0.86 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL4416822 | 0.85 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL4416819 | 0.85 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969999-A | Synthesis and application of novel bidentate nitrogen ligand palladium complex | 台州爱申特科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112430177-B | Synthesis method of montelukast sodium intermediate | 凯特立斯（深圳）科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-112430177-A | Synthesis method of montelukast sodium intermediate | 凯特立斯（深圳）科技有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2014081616-A1 | PREPARATION OF PRECURSORS FOR LEUKOTRIENE ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2010064109-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM AND ITS INTERMEDIATES | MAYUKA LABS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010064109-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM AND ITS INTERMEDIATES | MAYUKA LABS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | WO | disclosed |
| US-20100130745-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ETHENYLPHENYL ALCOHOLS | MCGARRITY JOHN | 2010-05-27 | — | — | US | disclosed |
| EP-1988079-A1 | Process for the preparation of optically active ethenylphenyl-alcohols | LONZA AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008035086-A2 | SYNTHESIS OF LEUKOTRIENE COMPOUNDS | ALMAC SCIENCES LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
| US-5856322-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | MERCK FROSST CANADA, INC. (CA) | 1999-01-05 | — | — | US | disclosed |
| EP-0480717-B1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-04-15 | — | — | EP | disclosed |
| EP-0500360-B1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-06-25 | — | — | EP | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130745-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ETHENYLPHENYL ALCOHOLS | ADH1A, ADH1C, ADH5 | CYSLTR1 4387/4885CYSLTR2 4204/4885ABCC1 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.